Ali Ayhan

Ali Ayhan

Auto-generated profile, based on publicly available information

Ali Ayhan

Department of Obstetrics and Gynecology, Baskent University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2008 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
AAAli Ayhan
Ali Ayhan
HCHusnu Celik
Husnu Celik
PDPolat Dursun
Polat Dursun
Although it does not have a long history of sentinel node evaluation (SLN) in female genital system cancers, there is a growing number of promising study results, despite the presence of some aspects that need to be considered and developed. It has been most commonly used in vulvar and uterine cervivcal cancer in gynecological oncology. According to these studies, almost all of which are prospective, particularly in cases where Technetium-labeled nanocolloid is used, sentinel node detection rate sensitivity and specificity has been reported to be 100%, except for a few cases. In the studies on cervical cancer, sentinel node detection rates have been reported around 80–86%, a little lower than those in vulva cancer, and negative predictive value has been reported about 99%. It is relatively new in endometrial cancer, where its detection rate varies between 50 and 80%. Studies about vulvar melanoma and vaginal cancers are generally case reports. Although it has not been supported with multicenter randomized and controlled studies including larger case series, study results reported by various centers around the world are harmonious and mutually supportive particularly in vulva cancer, and cervix cancer. Even though it does not seem possible to replace the traditional approaches in these two cancers, it is still a serious alternative for the future. We believe that it is important to increase and support the studies that will strengthen the weaknesses of the method, among which there are detection of micrometastases and increasing detection rates, and render it usable in routine clinical practice.

1 January 2013 in Turkish Journal of Pathology
Verified
Journal Article
Open access
PDPolat Dursun
Polat Dursun
AAAli Ayhan
Ali Ayhan
LMLevent Mutlu
Levent Mutlu
MCMete Caglar
Mete Caglar
AHAli Haberal
Ali Haberal
SKSelim Kirdar
Selim Kirdar
To evaluate the prevalence of HPV DNA and cervical cytological abnormalities, to compare cervical cytology results and HPV DNA and to define HPV types distribution in a large series of Turkish women who have undergone HPV analysis in hospitals that are members of the Turkish Gynecological Oncology Group. Between 2006 and 2010, a total of 6388 patients' data was retrospectively evaluated at 12 healthcare centers in Turkey. Demographic characteristics, cervical cytology results, HPV status and types were compared. The mean age of the patients was 38.9±10.2. Overall, 25% of the women were found to be HPV positive. Presence of HPV-DNA among patients with abnormal and normal cytology was 52% and 27%, respectively. There was significant difference with respect to decades of life and HPV positivity (p < 0.05). HPV was positive in (within the HPV (+) patients) 37%, 9%, 27%, 20%, 22%, and 41% of the ASCUS, ASC-H, LSIL HSIL, glandular cell abnormalities, and SCC cases respectively The most common HPV types in our study were as follows; HPV 16 (32%), HPV 6 (17%), HPV 11 (9%), HPV 18 (8%), HPV 31 (6%), HPV 51 (5%), HPV 33 (3%). In this hospital based retrospective analysis, HPV genotypes in Turkish women with normal and abnormal cytology are similar to those reported from western countries. Further population based prospective multicenter studies are necessary to determine non-hospital based HPV prevalence in Turkish women.

30 November 2010 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
GDGuldeniz Aksan Desteli
Guldeniz Aksan Desteli
MGMurat Gultekin
Murat Gultekin
AUAlp Usubutun
Alp Usubutun
KYKunter Yuce
Kunter Yuce
AAAli Ayhan
Ali Ayhan
Lymphadenectomy is an integral part of the staging system of epithelial ovarian cancer. However, the extent of lymphadenectomy in the early stages of ovarian cancer is controversial. The objective of this study was to identify the lymph node involvement in unilateral epithelial ovarian cancer apparently confined to the one ovary (clinical stage Ia).

1 January 2004 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
AAAli Ayhan
Ali Ayhan
MSMehmet Coskun Salman
Mehmet Coskun Salman
HCHusnu Celik
Husnu Celik
PDPolat Dursun
Polat Dursun
OOOzgur Ozyuncu
Ozgur Ozyuncu
MGMurat Gultekin
Murat Gultekin
Ovulation-inducing drugs have been widely used for various types of infertility since the beginning of 1960s and their use increases day by day parallel to the success achieved in fertility treatment. However, the researches performed in the last two decades have begun to discuss about the safety of these drugs and the risks associated with their use. Especially, the potential neoplastic effects of these drugs are increasingly questioned. The studies have discussed whether there is an association between the exposure to ovulation-inducing drugs and the incidence of various cancers. Moreover, several studies have been performed to reveal whether there is an increased risk of childhood cancers in children conceived after fertility treatment. The point we reached through the available data is that the risk of breast, uterine and invasive ovarian cancers is not increased, but the risk of borderline ovarian tumors might increase after such a therapy. The risk of cancer has been found similar for children conceived after fertility treatment and those conceived naturally. It should also be kept in mind that cancers are overdiagnosed in infertile women population because of the close medical surveillance, which may also contribute to the early detection of cancers. Although it is still early to state the last words on this topic, the possible association should be addressed when obtaining an informed consent before starting treatment.

1 January 2015
Verified
Journal Article
Closed access
AQAli Qzler
Ali Qzler
SDSelen Dogan
Selen Dogan
GMGunay Mamedbeyli
Gunay Mamedbeyli
SRSamed Rahatlı
Samed Rahatlı
AHA Nihan Haberal
A Nihan Haberal
AAAli Ayhan
Ali Ayhan